Pfizer Stock Price Forecast - PFE at $25: Market Prices a Meltdown Into a 7% Yield

NYSE:PFE – Market Still Pricing A Recovery Story Like A Broken Business

Earnings Reset: COVID Cliff Is Already In The Numbers, Not In The Narrative

Revenue And EPS Look Weak, But They Beat Expectations
At around $25–26 per share, linked in real time via NYSE:PFE, the market is still treating Pfizer as if the COVID revenue collapse, the 2026–2028 patent cliff and political risk will permanently cap earnings and force a dividend reset. Fiscal Q3 2025 revenue was $16.65B, down 5.9% year over year, with adjusted EPS at $0.87, down 17.9% year over year, but both figures beat consensus expectations, revenue by roughly 1% and EPS by more than 37%. The deterioration is exactly where analysts expected it to be, driven by weaker Paxlovid demand after heavy prior government stockpiling and lower infection levels, not by a collapse of the core business. Paxlovid’s revenue contribution has already fallen from about 15.5% of sales in Q3 2024 to roughly 7.4% in Q3 2025, showing that the COVID drag is shrinking in mix while non-COVID franchises take over as the earnings driver. Management reaffirmed 2025 revenue guidance at $61–64B and raised adjusted EPS guidance to $3.00–3.15 from $2.92–3.08, explicitly stating that this EPS range is de-risked against lower-than-anticipated COVID uptake, which means the negative COVID scenarios the market is still obsessed with are largely inside the current numbers.

Margins And Cost Base: The Hidden Strength
Despite COVID erosion, Pfizer’s adjusted gross margin in Q3 remains about 76%, firmly in the mid- to upper-70s range when you exclude the 50/50 profit split on Comirnaty. On operating costs, if you back out the one-time IPR&D charge related to the 3SBio deal, operating expenses actually fell by roughly $150M versus last year, which is not the profile of a company losing control of its cost base. A manufacturing optimization program is targeting $1.5B in savings by 2027 in Phase 1 alone, while a broader cost program aims at about $7.2B of net savings by 2027, with roughly $0.5B reinvested into R&D. A large portion of the cash outflow tied to severance and write-downs has already been recognized in 2024–2025, so from here more of the benefit should show up in the P&L than in incremental cash pain. This explains why Pfizer can hold 2025 EPS above $3 despite COVID headwinds and heavy pipeline spending, and why a forward dividend yield close to 7% is not automatically a value trap if execution on costs and growth continues along the current trajectory.

Ex-COVID Growth Engine: Vyndaqel, Nurtec, Padcev And The New Base

Specialty Cardio, Migraine And Oncology Are Scaling
The non-COVID portfolio is already visible in hard numbers, not just in slideware. The Vyndaqel family in ATTR-CM grew about 7% year over year in Q3, still behaving like a durable specialty cardiovascular franchise with unique mortality and hospitalization data backing its positioning. Nurtec, Pfizer’s oral CGRP drug, delivered roughly 22% operational growth in the quarter, proving that bolt-on deals like Biohaven can be scaled into global migraine franchises under Pfizer’s commercial infrastructure. Padcev posted about 13% global operational growth even after some demand was pulled forward in prior periods when the U.S. sales model shifted toward wholesalers. Across the board, recently launched and acquired products generated around $7.3B in revenue in the first nine months of 2025, up roughly 9% operationally, which is the actual replacement engine for COVID and early patent losses already feeding into the top line instead of being hypothetical.

LOE Overhang: Large, But Not A Business Cliff
Between 2026 and 2028, Pfizer expects to lose roughly $17–18B in annual revenue from loss of exclusivity across its portfolio, with the key “Big Four” drugs Eliquis, Ibrance, Xtandi and Xeljanz contributing about $15B and roughly 24% of company revenue. Because these are mostly small-molecule products, generic entry can destroy 80–90% of revenue within the first year in the worst case, and the market is clearly discounting that risk. The difference versus legacy disasters like Lipitor is that the exposure is diversified across multiple franchises rather than concentrated in a single drug representing over half of revenue, and Pfizer has already deployed tens of billions of dollars into replacement assets such as Seagen, 3SBio, Metsera, Biohaven and others. With ex-COVID products already growing from high single digits to double digits and LOE damage quantified and pre-funded, the patent cliff is a real earnings shock, but not an automatic business cliff unless pipeline execution fails across oncology and obesity simultaneously.

Pipeline And M&A: Oncology And Obesity As Core Optionality

Oncology: 3SBio’s 4404 And The Seagen Backbone
Management is repositioning oncology from a defensive story to a central growth pillar, using Seagen and 3SBio as the main building blocks. From 3SBio, the 4404 program has produced Phase II data in non-small cell lung cancer and colorectal cancer with encouraging depth and durability of response and manageable safety, giving Pfizer a credible candidate to act as a backbone checkpoint agent. The development plan is aggressive, with seven near-term 4404 trials planned and a second wave of up to ten additional indications and more than ten combination regimens, many pairing 4404 with Pfizer’s ADC portfolio inherited from Seagen. If 4404 can demonstrate superiority versus PD-1 plus VEGF or VEGF monotherapy in key lung and GI settings, Pfizer has a realistic opportunity to displace incumbents and create a high-value internal combo platform, something that most sell-side models still treat as low-value optionality in their probability-weighted pipelines.

Obesity And Cardiometabolic: Metsera Changes The Equation
In obesity and cardiometabolic disease, Pfizer’s initial efforts lagged first movers, but the Metsera acquisition reshapes the competitive position. Metsera brings a platform, not a single asset, including a monthly GLP-1 injectable with early data showing solid efficacy and tolerability, GLP-1 plus amylin combinations designed to deliver deeper and more durable weight loss, and an oral GLP-1 program matched to Pfizer’s historical strength in small-molecule development and global primary care commercialisation. Management has accepted around $0.16 of EPS dilution from Metsera and roughly $0.05 from 3SBio next year precisely to secure this platform, on top of its established cardiometabolic footprint built through Eliquis, Lipitor, Norvasc and Vyndaqel. With about fifteen obesity-related programs expected to move quickly in 2026, many targeting Phase III, Pfizer is positioning itself as a late but well-funded and deeply integrated player in a market that can support multiple winners, while current valuation multiples continue to reflect very little success probability for this franchise.

Balance Sheet, Cash Flow And Dividend: How Tight Is The Rope

Leverage And Free Cash Flow Are Manageable
Post-COVID, Pfizer chose to fund its major acquisitions such as Seagen largely with cash and debt rather than stock, which drove gross leverage to roughly 4x at the peak. That has already been reduced to around 2.7x, and management has been explicit that this is the leverage level they want to return to after the Metsera deal, which will temporarily push it higher again. Free cash flow reached about $4.57B in the first nine months of 2025 versus $4.03B in the same period of 2024, with 2024 full-year FCF at $9.84B and heavily back-loaded in Q4 due to wholesaler pre-buys and year-end collections. A realistic base case is roughly $10B of FCF in 2025, flat through 2028 as LOE and R&D offset each other, then a mid-single-digit growth rate as the new portfolio matures. With free cash flow margins projected to stay above 30% through 2029, Pfizer has room to service debt, fund its development agenda and maintain a substantial shareholder payout even if reported EPS looks volatile.

Dividend Sustainability: High Yield, Real But Not Guaranteed Risk
At a share price around $25–26, the dividend yield on PFE is approximately 6.7–6.9%, implying an annual cash cost of about $9.7–9.8B. That level is aggressive relative to current free cash flow, and the market is clearly embedding some probability that the dividend might be frozen or trimmed during the heavy LOE and investment years. Consensus forecasts still keep the payout ratio below roughly 80% on EPS through 2029, and management continues to signal a commitment to the dividend while prioritizing leverage back down toward 2.7x. The cost-saving program, which is targeted to deliver roughly $7.2B net by 2027 with $0.5B reinvested in R&D, offers structural support for both investment and distributions, but the risk is straightforward: if integration of Metsera, 3SBio and Seagen drags, or if LOE damage is worse than planned, management may choose to pause dividend growth or cut the payout to defend balance sheet flexibility. That possibility is exactly what the market is discounting into the current yield rather than ignoring.

Regulation, Trade And Politics: Headwinds Front-Loaded Into The Multiple

MFN Pricing, Manufacturing Commitments And Margin Pressure
Pfizer sits in the crosshairs of U.S. policy debates around drug pricing and manufacturing reshoring. It was the first major pharma company to reach a structured deal with the U.S. administration that effectively swaps a three-year exemption from import tariffs for increased domestic manufacturing commitments, removing uncertainty on two key fronts but locking in near-term margin pressure as production is rebalanced away from high-margin hubs such as Ireland and Belgium. The company faces additional pricing and volume pressure from Medicare negotiations and potential changes to recommended vaccine schedules, such as possible shifts in pediatric dosing for Prevnar 20 that could alter U.S. volume even without share loss to direct competitors. All of this is visible to the market and one of the main reasons PFE trades at roughly 8x forward earnings compared with a large-cap pharma median in the low- to mid-teens, reflecting a regulatory discount stacked on top of its operational risks.

China, Global Demand And The Long-Term Innovation Cycle
Not all macro developments are negative for Pfizer’s long-term positioning. China has started to incorporate Pfizer and peer drugs into its innovative drug catalog for private insurance, opening structurally growing demand in an aging population that is still underpenetrated in many specialty categories. Tariffs and trade measures are being used as bargaining chips rather than permanent barriers, and Pfizer’s willingness to sign early and secure exemptions suggests it can trade near-term margin for longer-term access and stability. Over the next decade, the heavier swing factor will be how effectively the industry uses AI and computational tools to compress R&D cycles and improve hit rates; Pfizer already demonstrated with Paxlovid that it can use high-throughput computational screening to dramatically shorten discovery timelines. For NYSE:PFE, the core question is not whether COVID is gone or whether tariffs exist, but whether the company can convert its very large oncology and obesity pipelines plus its manufacturing and cost reset into sustainable, ex-COVID earnings growth that justifies a valuation closer to 9–12x forward earnings and a medium-term fair value in the low-to-mid $30s rather than the mid-$20s where the stock currently trades.

That's TradingNEWS